The biphasic decay of blood viraemia in patients being treated for human immunode¢ciency virus type 1 (HIV-1) infection has been explained as the decay of two distinct populations of cells: the rapid death of productively infected cells followed by the much slower elimination of a second population the identity of which remains unknown. Here we advance an alternative explanation based on the immune response against a single population of infected cells. We show that the biphasic decay can be explained simply, without invoking multiple compartments: viral load falls quickly while cytotoxic T lymphocytes (CTL) are still abundant, and more slowly as CTL disappear. We propose a method to test this idea, and develop a framework that is readily applicable to treatment of other infections.
INTRODUCTION
Successful antiviral treatment of human immunode¢ciency virus type 1 (HIV-1) infection results in a biphasic exponential decline of blood viraemia (Perelson et al. 1997) . The ¢rst phase is steep, with 4 99% of virus disappearing in the ¢rst 1^2 weeks (t 1/2 of 1^2 days); the second is more gradual (t 1/2 of 10^40 days), continuing for a month or more until virus falls below detection limits. Because virus is known to infect several cell types in vivo (Schrager & D'Souza 1998) , early studies assumed the two phases re£ected the decay of two di¡erent populations of infected cells (Notermans et al. 1998; Perelson et al. 1997) . According to this conventional explanation, the ¢rst phase results from the decay of short-lived infected cells, while the second results from the slower decay of a minor population of longer-lived cells, perhaps macrophages or immune-privileged cells, the exact identity of which remains unknown (Finzi & Silliciano 1998) .
This explanation assumes that the immune system exerts a constant antiviral e¡ect during treatment. However, it is now known that treatment results in a profound reduction of cytotoxic T lymphocytes (CTL), which kill infected cells (Gray et al. 1999; Nixon et al. 1999; Ogg et al. 1999) . In light of increasing evidence that CTL play an important role in controlling infection Ogg et al. 1998; Schmitz et al. 1999) , we here advance an alternative explanation for the biphasic decay based on the e¡ects of the immune response. Using simple mathematical models, we show that the ¢rst phase of decay may re£ect CTL killing, while the second may re£ect the natural death rate of infected cells. This would imply that infected cells may be longer lived in vivo than generally thought; that HIV-1 may be relatively noncytotoxic; and that CTL killing may be responsible for more infected-cell death than virus-mediated cytolysis.
We conclude by proposing a simple experiment to test this idea.
THE MODEL
We consider the immune response against a single pool of infected cells. This interaction may be described by the following simple system of di¡erential equations, adapted from the standard model of virus dynamics (De Boer & Perelson 1998; Nowak & Bangham 1996) :
dy=dtˆ xy ¡ ay ¡ pyz,
dz=dtˆcy ¡ bz.
The variables x, y, and z denote uninfected cells, infected cells, and the lytic immune response (e.g. CTL), respectively. Uninfected cells are produced at a rate l, die at a per capita rate d, and are infected with a rate constant , the viral infectivity. 
. This general framework is applicable to treatment of many di¡erent infections.
This system makes a common simplifying assumption relative to the standard model. Because free virus is thought to be shortlived relative to infected cells (Perelson et al. 1996; Wei et al. 1995) , viral load can be treated as proportional to the number of infected cells . This means that the equilibrium expression for infected-cell frequency also describes baseline viral load. Relaxing this assumption changes neither the arguments nor the conclusions we present.
Antiviral treatment decreases the rate of new infection; this is re£ected in the model by a decrease in infectivity, (De Boer & Perelson 1998) . The extent of this decrease depends on the e¡ec-tiveness of the regimen, which we denote s. Values of s range from 0 to 1 depending on both host factors and treatment regimen. A value of sˆ0 corresponds to a completely e¡ective treatment, i.e. a regimen that reduces new infection to zero; so, for example, a value of sˆ0.05 would describe a regimen that reduces infectivity to 5% of its pre-treatment value. We incorporate this into the model by substituting s for in equation (1a,b) . This yields dx/dtˆl7 dx7s xy,
dy/dtˆs xy7 ay7 pyz ,
Now equilibrium infected-cell and CTL frequencies are given by . This threshold corresponds to the basic reproductive ratio (Anderson & May 1991) , and de¢nes the minimum e¡ectiveness that the treatment must have in order to lead to viral clearance. Note that even if e¡ectiveness falls short of this threshold (s 4 s t ), as long as e¡ectiveness is near the threshold (s º s t ), treatment may reduce viral load to arbitrarily low levels (see ½ 3(c)).
RESULTS

(a) Virus decay
We ¢rst consider the case where treatment is completely e¡ective, i.e. sˆ0. This reduces equation (2a) to dx/dtˆl7 dx and equation (2b) to dy/dtˆay7 pyz. Solving for y(t) from equation (2b,c) yields
, which describes a biphasic exponential decay in viral load (¢gure 1a). This can be understood as follows.
At equilibrium, two mechanisms control infection: CTL killing (7pyz) and natural infected-cell death (7ay), which includes viral cytotoxic e¡ects. Before treatment, these two drains are balanced by infection of new cells ( xy). Treatment prevents new infection, upsetting this balance. As a result, the number of infected cells falls from the combination of CTL killing and natural death; this accounts for the ¢rst phase. The loss of infected cells results in a loss of CTL, since CTL depend on the antigenic stimulus provided by infected cells for their maintenance (the cy term in equation (2c)). If CTL fall rapidlyöspeci¢cally, if their per capita death rate (b) is large relative to that of infected cells (a)ökilling soon becomes insigni¢cant, and the remaining infected cells will decay at a rate dominated by natural death (a), yielding the second phase. Because viral load is proportional to the number of infected cells, it too decays in two phases: a steep ¢rst phase due to the combined e¡ects of CTL killing and the natural death of infected cells, and a slower second phase driven by natural death alone. The analogy is of turning o¡ the tap on a split-basin sink (¢gure 2).
Analysis of the rate of decay of the ¢rst phase raises two points of interest. First, the rate of decay of the ¢rst phase is approximately a + pz * . Upon substitution for z (a) Initially, high CTL levels result in a steep decline in viral load; this is the ¢rst phase of viral load decay. As infected cells are cleared, CTL levels fall, and infected cells are killed more slowly, resulting in the second phase. The rate of decline decreases from a + pz *ˆ x * to a over time (all parameters as de¢ned in text). (b) Meanwhile, CTL decay rapidly, following a short shoulder phase, as antigenic stimulation disappears. Interestingly, it is possible that this rapid decay will bring CTL into quasi-equilibrium with what remains of the infected-cell population. This means that the CTL population will eventually decay at the natural infected-cell death rate. Simulation was for the system described by equation (2) with viral loadˆ10 6 y(t) and parameter values lˆ0. 05, aˆdˆ0.02, pˆcˆ1.0, bˆ0.15 , and ˆ0.5 before therapy and 0.0 thereafter ( sˆ0.0).
due to the combination of CTL killing and infected-cell death, the rate of this decay can be described solely in terms of viral infectivity ( ) and the equilibrium frequency of uninfected cells (x * ). Hence di¡erences in viral infectivity may account for observed di¡erences between patients in the slope of decay during the ¢rst phase. Second, because baseline viral load is given by (b/c)[( x*7 a)/p], a positive correlation between baseline viral load and rate of decay during the ¢rst phase, such as has been observed (Notermans et al. 1998; Perelson et al. 1997) , might be explained if patients di¡er from each other mainly in viral infectivity and uninfected-cell kinetics.
(b) CTL decay
Interestingly, CTL may also decay multiphasically in this model (¢gure 1b). At ¢rst, decay is slow; the CTL population is maintained near the pre-treatment equilibrium through stimulation by infected cells, which are still abundant. This results in a short shoulder phase. As infected cells decay, the cy term in equation (2c) becomes small and the rate of decay approaches b, yielding a second phase. Provided that b 4 a, one may also observe a third phase. In this case, the rapid decay of CTL brings it into quasi-steady-state equilibrium with the infectedcell population, which continues to decline. This is seen mathematically by rearranging equation (2c) to yield z * qssˆ( c/b) y(t); the rate of decay of CTL is now set by the natural infected-cell death rate, a. Interestingly, then, the CTL population may decay at a rate much slower than their per capita death rate, b. Figure 3a^c and table 1 show how the prominence of these phases depends on the relative death rates of CTL and infected cells and on other parameters.
We note that the behaviour of the CTL population depends on the particular mathematical form chosen for the CTL response. However, the possibilityödepending on viral and immune parameters, as shown in ¢gure 3a^c and table 1öof a biphasic decay of viral load is a general feature of treatment in the presence of a (lytic) immune response. More complicated models that include latently infected cells, longer-lived infected cells (¢gure 4 and ½ 4), and/or CTL precursors retain this feature (not shown).
(c) Imperfect treatment
For the more realistic case where s 4 0, provided that s 5 s t ² a/( x * ), treatment will result in viral clearance with behaviour similar to that for the case where treatment is perfect and sˆ0 (¢gure 3d ). The rate of decay during the ¢rst phase is now approximately a + pz * 7 s x * , which upon substitution yields (17s) x * . One might expect from this that more potent treatment regimens (i.e. those that are more e¡ective at reducing new infection and hence lead to lower values of s) cause steeper ¢rst-phase decays than less potent ones; indeed, this has been seen ). More likely is that imperfect treatment will have an e¡ect on the rate of decay of the second phase. If s 5 s t but is still small enough to lower viral load to very low levels, the rate of decay of the second phase will be smaller than a, and the half-life of viral decay during this phase will be correspondingly longer (¢gure 3d ).
DISCUSSION
The conventional explanation of the biphasic decay in treated HIV-1-infected patientsöthat the two phases correspond to two di¡erent infected-cell populations (Perelson et al. 1997) öassumes that the immune system exerts a constant antiviral e¡ect during treatment. Recent evidence argues against this assumption: the consensus is that treatment results in a massive decline of CTL, with important implications for disease management (Gray et al. 1999; Nixon et al. 1999; Ogg et al. 1999 If the per capita CTL death rate is relatively low (e.g. bˆ0.05 day 7 1 ), the CTL population persists at high levels long enough to kill most infected cells. As a result, viral load falls rapidly, and only one phase is observed. However, if the death rate is high (bˆ0.45 day 7 1 ), the CTL population falls quickly to quasi-equilibrium, and viral load will decay slowly; in this case a steep ¢rst phase may be observed, but its duration will be short. (b) Viral cytotoxicity. If the virus is very cytotoxic, or if infected cells are otherwise very short lived, a will be large (e.g. 0.10 day 7 1 ) and viral load will fall rapidly irrespective of CTL killing; in this case only a single steep phase is likely to be observed. However, if infected cells are longer lived (aˆ0.02 or 0.004 day 7 1 ), two phases will be observed. (c) Viral infectivity. The higher the infectivity, the steeper the ¢rst phase. (d ) Treatment e¡ectiveness. If e¡ectiveness is below a certain threshold ( s t , see ½ 3(c); here s t º 0:01), viral load may bounce back after a transient reduction (e.g. sˆ0.10). Interestingly, if e¡ectiveness is below but su¤ciently near the threshold, viral load may still be reduced to quite low levels (e.g. sˆ0.02). However, note that in this case the slope of decay of the second phase will be less than a (compare the case for sˆ0.02 with that for sˆ0.01 5 s t ). The e¡ects of di¡erences in l are similar to those of di¡erences in b (not shown); di¡erences in c and p do not change the shape of viral load or CTL decay (not shown). Viral load and CTL at time zero correspond to equilibrium values. Parameter values are lˆ0.05, ˆ0.5, aˆdˆ0.02, pˆcˆ1.0, bˆ0.15 , and sˆ0.0 unless otherwise noted.
infected populations do not have to be invoked to explain the biphasic decline. Instead, the model shows that the two phases may simply re£ect the two pathways by which infected cells die: CTL killing and natural death (¢gure 2a). At the start of treatment, both pathways are operative. Killing and death combine to drain the infected-cell pool quickly, and viral load falls accordingly fast; this results in the steep ¢rst phase (¢gure 2b). But the loss of infected cells means a loss of antigenic stimulation, which results in a relative loss of CTL and hence of CTL killing. The natural death pathway now plays the dominant role. With only one drain on the infected cell pool, viral load falls more slowly, resulting in the slower second phase (¢gure 2c). The argument holds for the more realistic case of imperfect treatment (½ 3 and ¢gure 3d ).
(a) Reinterpreting the rates of decay
Our results suggest a rede¢nition of the measured halflives of the two phases of decay. The conventional explanation proposes that the one-to two-day half-life of the ¢rst phase corresponds to a one-to two-day half-life of infected cells at the start of treatment; however, it says nothing about the relative contributions of CTL killing and natural death. By contrast, the new explanation proposes that most of the death of infected cells during this phase is due to CTL killing. The conventional explanation says the second phase corresponds to the decay of a second population of cells whose half-life is 10^40 days. The new explanation suggests that this phase may instead re£ect the natural death rate of infected cells, i.e. the death rate in the absence of CTL (which would correspond to a º 0.02^0.07 in the model). In other words, the new explanation predicts that, were it not for the immune response, infected cells would live on average for 1/a º14^50 days.
It is important to be clear that our results do not argue against the existence of reservoirs of viral replication (¢gure 4). However, in showing that the biphasic decay can be explained with only one infected population, we do challenge the view that the second phase must result purely from the decay of such a reservoir. This means that the second phase may be a poor re£ection of the size and decay rate of any long-lived reservoir (¢gure 4c,d ), contrary to previous reports (Perelson et al. 1997) .
Variability in slopes (Ding & Wu 1999; Notermans et al. 1998; Perelson et al. 1997 ) may be due to both virus and host factors. Interpatient di¡erences in many parameters may contribute to variability in the ¢rst phase (¢gure 3a^c). However, variability in the second phase is due principally to interpatient di¡erences in viral cytotoxicity (a) and treatment e¡ectiveness (s) (¢gure 3b,d ). In light of recent work that suggests that virus becomes increasingly pathogenic over the course of infection (Kimata et al. 1999) , one might expect rates of decay of the second phase to be greater in patients who have progressed to AIDS. However, pathogenicity depends on viral replication rate, infectivity, and tropism as well as on cytotoxicity, and so this expectation may not be borne out by conventional experimental observations. As for e¡ectiveness, as mentioned above, if treatment is not perfect (s 4 0), the rate of decay of the second phase will underestimate the natural death rate of infected cells (a) (¢gure 3d ).
(b) Viral cytotoxicity
Our ¢ndings also have implications for whether HIV-1 is cytotoxic or not in vivo. Under the conventional explanation, either conclusion is possible. If one ascribes the dominant role to cytotoxicity, the conclusion is that virus is cytotoxic for the vast majority of cells (the socalled`actively infected' pool, the decay of which accounts for the ¢rst phase in the conventional explanation) but is non-cytotoxic for others (the`long-lived' pool, the decay of which accounts for the second phase). If instead one ascribes the dominant role to CTL killing, the conclusion is that any long-lived population must be immune privileged. Our model suggests a middle road: in the simplest case, the short-and long-lived populations of the conventional explanation may be one and the same. In the presence of CTL, infected cells are short lived (t 1/2ˆ1^2 days); in their absence, they live much longer (t 1/2ˆ1 0^40 days). Assuming that activated uninfected CD4 + cells have a natural half-life of 40^50 days (Wang et al. 1998) , the new explanation suggests that HIV-1 may be relatively non-cytotoxic in vivo. This is consistent with the virus' known anti-apoptotic properties (Aillet et al. 1998; Conti et al. 1998; Meinl et al. 1998; Sandstrom et al. 1996; Scheuring et al. 1999; Wang et al. 1999) and various other observations (Klenerman & Zinkernagel 1997; Zinkernagel & Hengartner 1994) .
The new explanation requires that the death (or reversion) rate of CTL exceeds the natural death rate of infected cells (b 4 a) for the decay in viral load to be biphasic. In other words, infected cells must on average persist longer than CTL, otherwise infected cells will die out naturally before CTL levels fall, and there will be no second phase (¢gure 3a,b) . Which is the case for HIV-1? Recent studies that followed the decay of HIV-1-speci¢c CTL in treated individuals di¡er in their conclusions, but on balance suggest that e¡ectors die rapidly (t 1/2 5 1 week; b 4 0.10 day 71 ). One study (Nixon et al. 1999) found that activated e¡ectors, as measured by a functional assay, fell in frequency from 60 to 4 in 10 6 peripheral blood mononuclear cells in seven days, and stayed at low levels thereafter. This is consistent with a half-life of less than two days, and a value for b of 4 0.35 day 71 (¢gure 3a). Using tetramer staining (Altman et al. 1996) , another study (Ogg et al. 1999) found that the CTL population expressing the activation marker CD38 (Lund et al. 1998 ) decayed with a half-life that ranged from 15 to 60 days, depending on the patient, sometimes preceded by a marked early £uctuation (which the authors theorize may be due to tissue redistribution (Ogg et al. 1999) ) during the ¢rst week of treatment. This suggests a value for b of only 0.01^0.05 day 71 (¢gure 3a). A third study (Gray et al. 1999 ) also found that the tetramer-positive population declined slowly, but concluded that this population comprised predominantly memory CTL; e¡ectors, it suggested, are lost very rapidly. These di¡erences may be reconciled as more is learned about the functional di¡erences between CTL subsets. Still, it is important to keep in mind that e¡ector activity, usually as measured by direct ex vivo speci¢c lysis (Lau et al. 1994) , is known to fall rapidly following control of viral load in many viral infections; the same may be true following treatment of HIV-1. Simulations for (a) and (b) were for the system described by the following equations: dy 1 /dtˆ x 1 * ( y 1 + y 2 )7 a 1 y 1 7 p y 1 z; dy 2 /dtˆ x 2 * ( y 1 + y 2 )7 a2 y2 ¡ py2z ; dz/dtˆc( y 1 ‡ y 2 ) ¡ bz. Here y 1 and y 2 are major and minor infected-cell compartments, respectively, x 1 * and x 2 * denote the equilibrium frequencies of uninfected cells in these compartments, and other parameters are as de¢ned in the text. Parameter values were x 1 *ˆ1 .0, x 2 *ˆ0 .1, a 2ˆ0 .02, cˆpˆ1.0, bˆ0.15, ˆ0.5 before treatment and 0.0 thereafter, and a 1ˆ0 .20 in (a) and a 1ˆ0 .05 in (b) ( sˆ0.0). Simulations for (c) and (d ) were for the system dx 2 /dtˆldx 2 7 x 2 ( y 1 + y 2 ); dy 1 /dtˆ x 1 * ( y 1 + y 2 )¡a 1 y 1 7 py 1 z; dy 2 /dtˆ x 2 ( y 1 + y 2 )7 a 2 y2, dz/dtˆc( y1 ‡ y2) ¡ bz. Parameter values for (c) and (d ) were the same as those in (a) and (b), respectively, with lˆ1 £ 10 7 5 and dˆ0.02 ( sˆ0.0). Viral loads were calculated as 5 £ 10 6 y n (t).
By contrast, infected cells may live many weeks in the absence of host immune factors. One recent study (Wang et al. 1998) showed that in peripheral blood T lymphocytes that had been depleted of CD8 + T cells, stimulated with phytohaemagglutinin, and infected with di¡erent HIV-1 strains, the percentage of viable cells decayed with a half-life of 25^50 days, depending on the strain of virus, corresponding to aˆ0.014^0.028 day 71 in our model (¢gure 3b). This value is consistent with previously reported slopes of the second phase of biphasic decline (Notermans et al. 1998; Perelson et al. 1997) , supporting our new explanation (¢gure 1a). Hence it is plausible that e¡ector CTL die (or revert to resting or memory status) quicker than infected cells (i.e. that b 4 a) and that the biphasic decay results from di¡erent rates of CTL killing.
(c) Testing the model
The model proposes that CTL killing is primarily responsible for the ¢rst phase of viral load decay in treated HIV-1-infected patients; the same should be true for treated simian immunode¢ciency virus (SIV)-infected macaques (Kuroda et al. 1999 ). Hence the model should be readily testable by treating animals that have been depleted of CD8 + T cells (Schmitz et al. 1999) . If CTL killing is indeed primarily responsible for the ¢rst phase, the viral decay rate in these animals should be far less than in controls; in this case the decay rate should approximate the natural death rate of infected cells (a). If, on the other hand, little change in decay kinetics is observed, it is possible that the CTL response in HIV-1 infection is predominantly non-lytic, and is mediated by secreted soluble factors that prevent new infection (Barker et al. 1998; Wodarz & Nowak 1998) . Hence a`deplete, then treat' experiment could help determine the relative contributions of CTL killing and viral cytotoxicity to infected cell turnover in vivo.
In summary, our results represent a new interpretation of the e¡ects of combination therapy that suggests that CTL killing is more important, and HIV-1 is less cytotoxic, in vivo than previously thought. Because therapy may be reducing viraemia at the price of reducing the CTL response, strategies that also prime the CTL responseöi.e. that keep the CTL population high during the administration of antiviral drugsömay prove worthwhile if drugs are to be discontinued without long-term harm to the patient (Wodarz & Nowak 1999) . The framework we present may possibly be useful in analysing treatment of other viral infections, such as, perhaps, with hepatitis C virus (Neumann et al. 1998) , in the presence of a changing immune response.
